



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

JAN 29 2003

RECEIVED

In re application of:

LEBEL

Serial No.: 09/901,737

Filed: July 9, 2001

For: TRANSGENIC PLANTS
EXPRESSING CELLULOLYTIC
ENZYMES

Art Unit: 1638

Examiner: KUBELIK

Atty Docket 21043

Confirmation No.: 1621

SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

This Information Disclosure Statement is filed in accordance with 37 C.F.R. §§ 1.56, 1.97, and 1.98. The items listed on the enclosed Form PTO-1449 may be deemed to be pertinent to the above-identified application and are made of record to assist the Patent and Trademark Office in its examination of this application. Copies of the listed items are enclosed herewith. The Examiner is respectfully requested to fully consider the items in relation to this application and to indicate that each reference was considered by returning a copy of the initialed PTO 1449 forms.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicants reserve the right to dispute any of the listed documents as prior art during examination.

Further, Applicants do not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application. Further, the submission of the Information Disclosure Statement is not to be construed as a representation that a search has been made or that no other material information may exist.

In accordance with 37 C.F.R. § 1.97(c), since this Information Disclosure Statement is being filed after the mailing of a first Office Action on the merits but before the mailing date of a final action, this filing is accompanied by the fee set forth in 37 C.F.R. § 1.17 (p).

The Commissioner is authorized to charge \$180.00 for payment of this submission pursuant to 37 C.F.R. § 1.17(p), to Applicant's credit card. A Credit Card Payment Form is attached hereto. The Commissioner is authorized to charge any additional fees under 37 C.F.R. § 1.17 that may be required, to Deposit Account No. 50-1744 in the name of Syngenta.

Respectfully submitted,



Randee S. Schwartz
Attorney for Applicants
Registration No. 45,085

Syngenta Biotechnology, Inc.
P. O. Box 12257
Research Triangle Park, NC 27709-2257
Telephone: 919-765-5098
Date: 1/22/03